EMA Moves To Elevate Role Of Non-Clinical Data In Pediatric Cancer Drug Development

PIPs Are Increasingly Being Based On Drug’s Mechanism Of Action

Healthcare, teddy bear and child cancer patient holding her toy for support or comfort. Medical, recovery and girl kid with leukemia standing after treatment or chemotherapy in a medicare hospital.
EMA wants to support the development of pediatric oncology medicines (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from EMA

More from Agency Leadership